The Latest Breaking News from Novo Nordisk

Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments, refutes claims that Novo Nordisk AS‘s (NYSE:NVO) Ozempic demonstrates anti-aging properties. Johnson disputed a post on social platform X suggesting the diabetes drug reverses biological aging by 3.1 years.

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

The popular weight loss drug shrank the liver of mice by nearly half their size, researchers said

It’s not actually that hard to imagine. Have you been on a diet? Have you ever lost weight? If so, the chances are you put that weight right back on again. I’ve done it. Oprah’s done it. Sam Smith have done it. My cat did it (RIP, my boy).

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?